期刊文献+

放大色素结肠镜观察FAS、Ki-67在直肠异常隐窝病灶中的表达

Overexpression of FAS and Ki-67 in aberrant crypt foci from patients with adenoma
下载PDF
导出
摘要 目的:观察FAS、Ki-67在结肠腺瘤、异常隐窝病灶(aberrant crypt foci,ACF)中的表达,探讨脂肪酸合成酶(fatty acid synthase,FAS)、增殖细胞核抗原(Ki-67)的异常表达在结直肠癌癌前病变形成中的意义.方法:对34例结肠镜确诊为腺瘤性息肉患者,常规内镜检查结束时,用0.2%的亚甲蓝溶液染色直肠黏膜,然后使用放大结肠镜观察直肠寻找ACF.对结肠腺瘤性息肉、ACF及正常黏膜活检标本进行免疫组织化学分析其FAS和Ki-67的表达.结果:34例结肠腺瘤性息肉患者,其中31例直肠发现ACF,共发现并活检ACF166处(其中伴异型增生14处,不伴异型增生152处).FAS、K i-67在结肠腺瘤、A C F中呈异常高表达(P<0.01).伴异型增生ACF中FAS、Ki-67表达较不伴异型增生ACF无明显上调.结论:FAS、Ki-67在结直肠癌的癌前病变(腺瘤、ACF)呈异常高表达.结直肠癌的癌前病变存在细胞能量代谢异常及异常增殖,在ACF阶段就已经异常增殖明显,抑制FAS有望成为结直肠癌预防、治疗的靶点. AIM:To detect the expression of fatty acid synthase(FAS) and Ki-67 in colonic adenoma and aberrant crypt foci to explore their significance in the formation of precancerous lesions.METHODS:Aberrant crypt foci(ACF) in the rectum of 34 patients with adenoma were identified by magnification chromoendoscopy(MCE) after staining with 0.2% methylene blue solution.Specimens with ACF were biopsied to detect the expression of FAS and Ki-67 by immunohistochemistry.RESULTS:A total of 166 ACF were found in 31 patients,of which 14 had atypical hyperplasia and 152 had no atypical hyperplasia.The expression of FAS and Ki-67 in colonic adenoma and ACF were significantly higher than that in normal tissue(all P 0.01).There was no significantdifference in the expression of FAS and Ki-67 between ACF with and without dysplasia.CONCLUSION:The expression of FAS and Ki-67 is higher in colorectal precancerous lesions.FAS may be used as a target for preventing and treating colorectal cancer.
出处 《世界华人消化杂志》 CAS 北大核心 2012年第15期1371-1375,共5页 World Chinese Journal of Digestology
关键词 异常隐窝病灶 脂肪酸合成酶 KI-67 放大色素内镜 Aberrant crypt foci Fatty acid synthase Ki-67 Magnification chromoscopy
  • 相关文献

参考文献3

二级参考文献29

  • 1Sheng H,Shao J,Morrow JD,Beauchamp RD,DuBois RN.Modulation of apoptosis and Bcl-2expression by prostaglandin E2 in human colon cancer cells.Cancer Res 1998;58:362-366.
  • 2McEntee MF,Chiu CH,Whelan J.Relationship of beta-catenin and Bcl-2 expression to sulindacinduced regression of intestinal tumors in Min mice.Carcinogenesis 1999;20:635-640.
  • 3Kohno H,Yoshitani S,Takashima S,Okumura A,Hosokawa M,Yamaguchi N,Tanaka T.Troglitazone,a ligand for peroxisome proliferatoractivated receptor gamma,inhibits chemicallyinduced aberrant crypt foci in rats.Jpn J Cancer Res 2001;92:396-403.
  • 4Tanaka T,Kohno H,Yoshitani S,Takashima S,Okumura A,Murakami A,Hosokawa M.Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats.Cancer Res 2001;61:2424-2428.
  • 5Os awa E,Naka j ima A,Wada K,I shimine S,Fujisawa N,Kawamori T,Matsuhashi N,Kadowaki T,Ochiai M,Sekihara H,Nakagama H.Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice.Gastroenterology 2003;124:361-367.
  • 6Chen L,Bush CR,Necela BM,Su W,Yanagisawa M,Anastasiadis PZ,Fields AP,Thompson EA.RS5444,a novel PPARgamma agonist,regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells.Mol Cell Endocrinol 2006;251:17-32.
  • 7Su W,Bush CR,Necela BM,Calcagno SR,Murray NR,Fields AP,Thompson EA.Differential expression,distribution,and function of PPARgamma in the proximal and distal colon.Physiol Genomics 2007;30:342-353.
  • 8Morin PJ,Vogelstein B,Kinzler KW.Apoptosis and APC in colorectal tumorigenesis.Proc Natl Acad Sci U S A 1996;93:7950-7954.
  • 9Morin PJ,Sparks AB,Korinek V,Barker N,Clevers H,Vogelstein B,Kinzler KW.Activation of betacatenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC.Science 1997;275:1787-1790.
  • 10Cory S,Vaux DL,Strasser A,Harris AW,Adams JM.Insights from Bcl-2 and Myc:malignancy involves abrogation of apoptosis as well as sustained proliferation.Cancer Res 1999;59:1685s-1692s.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部